Background
Dr. Nirmish Singla is an Associate Professor of Urology and Oncology in the Brady Urological Institute at Johns Hopkins University, where he serves as the Director of Translational Research in Genitourinary Oncology. He is also the Director of the Kidney and Testicular Cancer Programs and co-directs the Upper Tract Urothelial Cancer (UTUC) Program as a founding member of the first-ever UTUC Multidisciplinary Clinic. He serves the Brady in a leadership capacity as Vice Chair and Physician Advisor for Quality, Safety, & Service.
Dr. Singla received his undergraduate degree (B.S.E.) in Biomedical Engineering from the University of Michigan and his medical degree (M.D.) from the University of Michigan Medical School, where he was supported by a full-tuition Dean’s Merit Scholarship. He went on to complete his residency training in Urologic Surgery at the University of Texas Southwestern Medical Center (UTSW). Following his residency, he received an NIH/NCI Ruth L. Kirschstein National Research Service Award T32 grant and spent an additional year at UTSW as a postdoctoral research fellow in Urologic Oncology with a specialized translational focus in kidney cancer through the Physician Scientist Training Program. During this time, he earned a Master of Science in Clinical Science (M.S.C.S.) degree through the Center for Translational Medicine at UTSW and helped develop and pioneer a Physician Administrative Fellowship program. He then completed an advanced surgical fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York through the Society of Urologic Oncology (SUO) before joining the faculty at Johns Hopkins.
Dr. Singla’s clinical practice spans the complete spectrum of genitourinary oncology, including adrenal, kidney, upper tract, bladder, prostate, penile, urethral, and testicular cancers. His surgical approaches include mastery of both open and minimally-invasive (endoscopic, laparoscopic, and robotic) techniques. Dr. Singla provides personalized and compassionate care for patients affected by urologic cancer by integrating cutting-edge technologies and multidisciplinary approaches to treatment.
As both a surgeon-scientist and clinical trialist, Dr. Singla’s overarching goal is to help scientific discoveries in the laboratory materialize for patients with urologic cancers in the clinic. He runs a well-funded, multidisciplinary, translational laboratory specializing in kidney cancer, testicular cancer, and UTUC. Dr. Singla has co-authored over 200 articles and textbook chapters, and he has developed an international reputation as a thought leader in urologic oncology. He has secured a substantial amount of research funding and serves as the lead PI on multiple grants from federal, foundational, intramural, and private sources across various GU malignancies.